Assessment of the safety, tolerability and pharmacodynamics after administration of one dose of AZD8601 to male patients with type II diabetes mellitus (T2DM)

Trial Identifier: D9150C00001
Sponsor: AstraZeneca
Collaborator:
PAREXEL International GmbH
Spandauer Damm 130
14050
Berlin, Germany
NCTID:: NCT02935712
Start Date: December 2016
Primary Completion Date: August 2017
Study Completion Date: January 2018
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
German Translation

Trial Locations

Country Location
Germany Berlin, Germany, 14050